SecBot SecBot
SECBOTREPLAY Home › Report › BCRX

BCRX · BioCryst is discontinuing its internal discovery programs and closing…

BIOCRYST PHARMACEUTICALS INC · 8-K filed Jun 29, 2026 at 07:06 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Jun 29, 2026 at 07:06 ET

BioCryst is discontinuing its internal discovery programs and closing its Birmingham, Alabama research facility by year-end 2026, shifting to an external innovation model. The restructuring lowers 2026 non-GAAP operating expense guidance by $30M to $420-440M, while revenue guidance of $635-660M is reaffirmed. Phase 3 ALPHA-ORBIT enrollment for navenibart is complete with top-line data expected in Q3 2027, and the manufacturing delay for ORLADEYO oral pellets is resolved with availability in early August.

  • Board approved plan to discontinue internal discovery programs and close Birmingham Discovery Center of Excellence facility by end of 2026.
  • Restructuring costs (contract termination, lease termination, severance, etc.) are not yet estimable; an amended 8-K will be filed when determined.
  • 2026 non-GAAP operating expense guidance reduced from $450-470M to $420-440M.
  • 2026 ORLADEYO revenue guidance reaffirmed at $625-645M; total company revenue guidance reaffirmed at $635-660M.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access